Researchers monitoring the brain activity of a patient with a severe binge-eating problem reported that Eli Lilly's GLP-1 ...

Researchers reported that Eli Lilly’s GLP-1 weight-loss drug appeared to temporarily suppress food-craving signals in the ...

Eli Lilly and Company (NYSE:LLY) is one of the 15 Best Aggressive Growth Stocks to Buy Right Now. On November 7, TD Cowen ...

Lilly shines for growth seekers while J&J offers steady, lower-risk stability as both pharma giants advance pipelines and ...

The trillion-dollar club has become crowded with mostly tech names riding the AI boom. Eli Lilly might soon join them for a ...

The two drugmakers swiftly denied any affiliation with Mangoceuticals, who claimed it had partnered with them.

Research reveals Eli Lilly's GLP-1 drug, tirzepatide, temporarily suppresses food cravings in a patient's brain reward center. While initial effects were promising, the impact faded over time. Results ...

Eli Lilly is well on its way to the trillion-dollar club. The stock price is up 30% so far this year; with a total ...

GLP-1 RAs, particularly semaglutide and tirzepatide, outperform older medications in achieving significant weight loss in adults with and without type 2 diabetes. Semaglutide and tirzepatide met ...

Eli Lilly and Novo Nordisk’s competition in weight-loss drugs has affected thousands of jobs between Charlotte and Raleigh. Who is winning?

Over the past couple of years, Eli Lilly (NYSE: LLY) has emerged as the leader in the weight loss market. The company's ...

The drugmaker said Monday that it has started selling higher doses of the injectable obesity treatment for $349 a month to ...